TL;DR
The intervention appears safe and effective relative to both unilateral MIGS and immediately sequential bilateral cataract surgery.
PURPOSE Secondary glaucoma encompasses a broad spectrum of disease entities arising from diverse ocular pathologies and is often refractory to conventional treatment. Glaucoma drainage devices (GDDs) have therefore become an important surgical option. This study evaluates the efficacy and safety of the PAUL® Glaucoma I...
To report 1-year surgical outcomes of phaco-iStent and phaco-iStent inject W implantation in Japanese patients with normal-tension glaucoma (NTG) and to explore factors associated with surgical failure. This single-centre retrospective study included 51 eyes of 38 consecutive patients with NTG who underwen...
At 1 year, the modified retrobulbar/intraconal placement of the Ahmed ClearPath 250 GDD achieves substantial intraocular pressure lowering, reduces the need for topical medications, and supports the short-term feasibility of this promising procedure.
A BSTRACT Lens-induced glaucoma (LIG), a sight threatening secondary glaucoma disease, prevalent in India, requires early management for restoring vision and preventing blindness. Despite its clinical significance, limited data exists regarding visual outcomes following current management approaches in phacom...
PURPOSE To evaluate the gel stent's intraocular pressure (IOP)-lowering safety and effectiveness in angle closure glaucoma (ACG). METHODS Prospective, multicenter, nonrandomized, 12-month, interventional study. Adults with ACG (iridotrabecular contact in ≥2 quadrants, glaucomatous optic disc damage, and visual field...
AIM The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial supports selective laser trabeculoplasty (SLT) as first-line glaucoma treatment; however, local real-world data are limited. We evaluated the real-world outcomes of SLT on intraocular pressure (IOP) and medication burden in a regional Aotearoa New Zealand...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
